Opinion

Video

Final Thoughts

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

The panel discussion concludes with final thoughts on the future landscape of newly diagnosed multiple myeloma.

Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
Multiple myeloma cells depiction | Image Credit: © DZMITRY - stock.adobe.com
November 23rd 2024

Belantamab Mafodotin Achieves Secondary End Point for Treatment of Relapsed, Refractory Multiple Myeloma

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Oncology Edition
April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

Multiple Myeloma is a cancer of plasma cells, a type of white blood cell found in bone marrow - Image credit: kamonrat | stock.adobe.com
November 12th 2024

Bispecific Antibody Receives FDA Orphan Drug Designation for the Treatment of Multiple Myeloma

Kennedy Ferruggia, Assistant Editor
Multiple myeloma cells | Image Credit: © Сергей Косилко - stock.adobe.com
November 11th 2024

Johnson & Johnson Seeks FDA Approval of Daratumumab for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Image Credit: © CHA - stock.adobe.com
November 6th 2024

Bone Marrow Adipocytes May Offer Early Detection of MGUS Progression to Multiple Myeloma

Alexandra Gerlach, Associate Editor
Image Credit: © Сергей Косилко - stock.adobe.com
November 1st 2024

Carfilzomib, Lenalidomide, and Dexamethasone: A Curative Approach for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor